Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study

We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged >= 20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013-2015). Treatments were inferred from reimbursed drugs, and procedures registered in national health insurance databases. This real-world population-based study allows to assess patients usually excluded from clinical trials such as those with comorbidities, other malignancies (12%), and advanced age (28% are >= 80 yr old). Our data show that the majority of older... Mehr ...